دورية أكاديمية
G6PD Polymorphisms and Hemolysis After Antimalarial Treatment With Low Single-Dose Primaquine: A Pooled Analysis of Six African Clinical Trials.
| العنوان: | G6PD Polymorphisms and Hemolysis After Antimalarial Treatment With Low Single-Dose Primaquine: A Pooled Analysis of Six African Clinical Trials. |
|---|---|
| المؤلفون: | Sepúlveda N; Department of Infection Biology, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.; CEAUL - Centro de Estatística e Aplicações da Universidade de Lisboa, Lisbon, Portugal., Grignard L; Department of Infection Biology, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom., Curry J; LGC Genomics, Hertfordshire, United Kingdom., Mahey L; LGC Genomics, Hertfordshire, United Kingdom., Bastiaens GJH; Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, Netherlands., Tiono AB; Department of Public Health, Centre National de Recherche et de Formation sur le Paludisme & Institut National de Santé Publique, Ouagadougou, Burkina Faso., Okebe J; Department of International Public Health, Liverpool School of Tropical Medicine, Liverpool, United Kingdom., Coulibaly SA; Department of Public Health, Centre National de Recherche et de Formation sur le Paludisme & Institut National de Santé Publique, Ouagadougou, Burkina Faso., Gonçalves BP; Department of Infection Biology, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.; Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, United Kingdom., Affara M; MRC Unit The Gambia at the London School of Hygiene & Tropical Medicine, Fajara, Gambia., Ouédraogo A; Department of Public Health, Centre National de Recherche et de Formation sur le Paludisme & Institut National de Santé Publique, Ouagadougou, Burkina Faso., Bougouma EC; Department of Public Health, Centre National de Recherche et de Formation sur le Paludisme & Institut National de Santé Publique, Ouagadougou, Burkina Faso., Sanou GS; Department of Public Health, Centre National de Recherche et de Formation sur le Paludisme & Institut National de Santé Publique, Ouagadougou, Burkina Faso., Nébié I; Department of Public Health, Centre National de Recherche et de Formation sur le Paludisme & Institut National de Santé Publique, Ouagadougou, Burkina Faso., Lanke K; Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, Netherlands., Sirima SB; Department of Public Health, Centre National de Recherche et de Formation sur le Paludisme & Institut National de Santé Publique, Ouagadougou, Burkina Faso., Dicko A; Malaria Research and Training Centre, Faculty of Pharmacy and Faculty of Medicine and Dentistry, University of Sciences, Techniques and Technology of Bamako, Bamako, Mali., d'Alessandro U; MRC Unit The Gambia at the London School of Hygiene & Tropical Medicine, Fajara, Gambia.; Department of Disease Control, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom., Clark TG; Department of Infection Biology, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.; Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, United Kingdom., Campino S; Department of Infection Biology, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom., Chen I; Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, United States., Eziefula AC; Department of Infection Biology, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.; Department of Global Health and Infection, Brighton and Sussex Medical School, University of Sussex, Brighton, United Kingdom., Gosling R; Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, United States., Bousema T; Department of Infection Biology, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.; Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, Netherlands., Drakeley C; Department of Infection Biology, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom. |
| المصدر: | Frontiers in genetics [Front Genet] 2021 Apr 09; Vol. 12, pp. 645688. Date of Electronic Publication: 2021 Apr 09 (Print Publication: 2021). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation Country of Publication: Switzerland NLM ID: 101560621 Publication Model: eCollection Cited Medium: Print ISSN: 1664-8021 (Print) Linking ISSN: 16648021 NLM ISO Abbreviation: Front Genet Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Lausanne : Frontiers Research Foundation. |
| مستخلص: | Primaquine (PQ) is an antimalarial drug with the potential to reduce malaria transmission due to its capacity to clear mature Plasmodium falciparum gametocytes in the human host. However, the large-scale roll-out of PQ has to be counterbalanced by the additional risk of drug-induced hemolysis in individuals suffering from Glucose-6-phospate dehydrogenase (G6PD) deficiency, a genetic condition determined by polymorphisms on the X-linked G6PD gene. Most studies on G6PD deficiency and PQ-associated hemolysis focused on the G6PD A- variant, a combination of the two single nucleotide changes G202A (rs1050828) and A376G (rs1050829), although other polymorphisms may play a role. In this study, we tested the association of 20 G6PD single nucleotide polymorphisms (SNPs) with hemolysis measured seven days after low single dose of PQ given at the dose of 0.1 mg/kg to 0.75 mg/kg in 957 individuals from 6 previously published clinical trials investigating the safety and efficacy of this drug spanning five African countries. After adjusting for inter-study effects, age, gender, baseline hemoglobin level, PQ dose, and parasitemia at screening, our analysis showed putative association signals from the common G6PD mutation, A376G [-log Competing Interests: JC and LM were employed by the company LGC Genomics. The remaining authors declare that the research was conducted in the absence of any commercial and financial relationships that could be construed as a potential conflict of interest. (Copyright © 2021 Sepúlveda, Grignard, Curry, Mahey, Bastiaens, Tiono, Okebe, Coulibaly, Gonçalves, Affara, Ouédraogo, Bougouma, Sanou, Nébié, Lanke, Sirima, Dicko, d’Alessandro, Clark, Campino, Chen, Eziefula, Gosling, Bousema and Drakeley.) |
| References: | Antimicrob Agents Chemother. 2019 Sep 23;63(10):. (PMID: 31383656) PLoS One. 2018 Jan 11;13(1):e0190272. (PMID: 29324864) PLoS Genet. 2015 Feb 11;11(2):e1004960. (PMID: 25671784) Nature. 2015 Oct 1;526(7571):82-90. (PMID: 26367797) Front Pediatr. 2020 Jun 12;8:293. (PMID: 32596192) J Infect Dis. 2018 Mar 28;217(8):1298-1308. (PMID: 29342267) Nat Genet. 2020 Dec;52(12):1314-1332. (PMID: 33230300) Antimicrob Agents Chemother. 2017 Apr 24;61(5):. (PMID: 28289025) BMC Med. 2016 Mar 08;14:40. (PMID: 26952094) Nat Genet. 2014 Nov;46(11):1197-204. (PMID: 25261933) PLoS Med. 2012;9(11):e1001339. (PMID: 23152723) Nature. 2015 Oct 1;526(7571):68-74. (PMID: 26432245) Elife. 2017 Jan 09;6:. (PMID: 28067620) Antimicrob Agents Chemother. 2010 May;54(5):1762-8. (PMID: 20194698) BMC Infect Dis. 2009 May 21;9:69. (PMID: 19460160) Proc Natl Acad Sci U S A. 1988 Jun;85(11):3951-4. (PMID: 2836867) Blood. 1989 Nov 15;74(7):2550-5. (PMID: 2572288) J Infect Dis. 2017 Jul 1;216(1):45-54. (PMID: 28541483) Malar J. 2014 Jul 11;13:270. (PMID: 25015414) Drug Metab Pharmacokinet. 2018 Dec;33(6):250-257. (PMID: 30366777) Malar J. 2012 Dec 19;11:424. (PMID: 23253143) Malar J. 2016 Jun 10;15:316. (PMID: 27287612) J Infect Dis. 2017 Aug 15;216(4):457-467. (PMID: 28931236) Malar J. 2018 Mar 20;17(1):120. (PMID: 29558929) Lancet Infect Dis. 2014 Feb;14(2):130-9. (PMID: 24239324) Trends Parasitol. 2011 Jan;27(1):11-6. (PMID: 20846906) Lancet Infect Dis. 2016 Jun;16(6):674-684. (PMID: 26906747) |
| معلومات مُعتمدة: | MR/R020973/1 United Kingdom MRC_ Medical Research Council; MR/M01360X/1 United Kingdom MRC_ Medical Research Council; MR/R025576/1 United Kingdom MRC_ Medical Research Council; MR/N010469/1 United Kingdom MRC_ Medical Research Council; United Kingdom WT_ Wellcome Trust |
| فهرسة مساهمة: | Keywords: clinical trials; drug safety; genetic association study; hemoglobin; malaria |
| تواريخ الأحداث: | Date Created: 20210426 Latest Revision: 20240504 |
| رمز التحديث: | 20240504 |
| مُعرف محوري في PubMed: | PMC8062977 |
| DOI: | 10.3389/fgene.2021.645688 |
| PMID: | 33897764 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!